Zim Laboratories Limited — PPTs, 07-08-2025: Investor Presentation

**Financial Highlights:**

Q1FY26 operating income for Zim Laboratories was ₹71.8 Cr, down 12.3% YoY. EBITDA declined 36.7% to ₹5.7 Cr, with margins at 7.9%. The company reported a net loss of ₹1.9 Cr, impacted by lower revenue and higher costs. Dossier outlicensing fees contributed ₹4.5 Cr.

**Strategic Initiatives & Growth Drivers:**

Zim invested ₹7.9 Cr in R&D, including ₹1.9 Cr for BE studies and regulatory filings, underscoring its focus on pipeline advancement. A new BD team with regional heads was onboarded for Africa, CIS, LatAm, MENA, and SE Asia to drive market expansion.

**Business Developments:**

The company filed 1 NIP in EU and 14 ODS/NIPs in other markets, securing 5 Marketing Authorizations, including two for oral films via its Australian subsidiary. India business grew 30.2% to ₹10.0 Cr, partially offsetting export decline due to geopolitical issues.

**Market Position & Competitive Advantage:**

Pharma business remains the core, contributing 78% of revenue. The 90-member R&D team and an extensive product pipeline, including 8 NIPs filed in EU, highlight the company's innovation-driven competitive advantage in specialized formulations.

**Investor Implications:**

While Q1 faced headwinds from geopolitical instability impacting exports, significant R&D investment and a robust product pipeline suggest positive long-term growth potential. Investors should monitor execution risk related to market recovery and new product commercialization.